Get the Stockscreener App
9.4762
0.33%
-0.0438
Anika Therapeutics Inc stock is traded at $9.4762, with a volume of 61,385.
It is down -0.33% in the last 24 hours and up +0.73% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
See More
Previous Close:
$9.52
Open:
$9.57
24h Volume:
61,385
Relative Volume:
0.42
Market Cap:
$136.57M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-1.8691
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
-0.43%
1M Performance:
+0.73%
6M Performance:
-13.74%
1Y Performance:
-41.50%
1-Day Range:
$9.47
$9.60
1-Week Range:
$9.155
$9.60
52-Week Range:
$7.8701
$18.37
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.47 | 137.29M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
124.18 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.66 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.62 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
(ANIK) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Can Anika Therapeutics Inc. stock withstand economic slowdownJuly 2025 Action & Growth Oriented Trade Recommendations - bollywoodhelpline.com
How Anika Therapeutics Inc. stock performs in rising dollar environmentFed Meeting & Smart Allocation Stock Tips - bollywoodhelpline.com
Anika Therapeutics (NASDAQ:ANIK) Share Price Passes Above 200-Day Moving AverageTime to Sell? - MarketBeat
Anika Therapeutics Builds Focused Platform For Joint Health Care - Kalkine Media
Will Anika Therapeutics Inc. stock benefit from infrastructure spendingMarket Risk Report & Long Hold Capital Preservation Plans - ulpravda.ru
Anika Therapeutics (NASDAQ:ANIK) Given “Outperform” Rating at Barrington Research - Defense World
(ANIK) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Barrington Research Reiterates Outperform Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Anika Therapeutics (ANIK): Barrington Research Maintains Outperf - GuruFocus
Anika Therapeutics names Stephen Griffin as new CEO - Investing.com
Is Anika Therapeutics Inc. stock trading near support levels2025 Key Lessons & Risk Controlled Swing Alerts - Улправда
Anika Therapeutics Announces CEO Transition and Governance Changes - TipRanks
Will Anika Therapeutics Inc. (AKP) stock see insider accumulationMarket Sentiment Report & Growth Focused Stock Pick Reports - ulpravda.ru
Anika Therapeutics Announces Leadership Transition - Ortho Spine News
Is Anika Therapeutics Inc. (AKP) stock inflation resilientJuly 2025 PreEarnings & Growth Oriented Trade Recommendations - Улправда
How Anika Therapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Review & Expert Verified Stock Movement Alerts - Улправда
Anika Therapeutics, Inc. Announces Chief Executive Officer Changes - MarketScreener
Anika Therapeutics names Stephen Griffin as new CEO By Investing.com - Investing.com Australia
Cosmetic Surgery Market Is Booming Worldwide 2025-2032 | - openPR.com
Anika Therapeutics Shares Plunge 27.42% After Clinical Trial Results Fail to Meet Primary Endpoints - Intellectia AI
Why Anika Therapeutics Inc. stock remains on watchlistsMarket Activity Report & Community Trade Idea Sharing - Улправда
Market Pulse: Why Anika Therapeutics Inc. stock is trending among retail tradersDip Buying & Daily Technical Forecast Reports - Улправда
Is Anika Therapeutics Inc. stock attractive for retirement portfolios2025 AllTime Highs & Low Risk Entry Point Guides - DonanımHaber
Why Anika Therapeutics Inc. stock could see breakout soonWeekly Investment Recap & Capital Protection Trading Alerts - DonanımHaber
Regenerative Medicine (Bone and Joint) Market Is Going to Boom | Anika Therapeutics, Inc, Arthrex, Inc. - openPR.com
Why Anika Therapeutics Inc. stock is trending among retail tradersQuarterly Profit Review & Expert Curated Trade Setup Alerts - Улправда
(ANIK) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Income Plays: Why Anika Therapeutics Inc. stock is trending among retail tradersJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
Anika Therapeutics’ Earnings Call: Growth Amid Challenges - MSN
Is the Options Market Predicting a Spike in Anika Therapeutics Stock? - sharewise.com
Is Anika Therapeutics Inc a good long term investmentTechnical Analysis Insights & Unlock Free Weekly Portfolio Checkups - earlytimes.in
Europe Viscosupplementation Market Detailed In New Research - openPR.com
Responsive Playbooks and the ANIK Inflection - Stock Traders Daily
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP - GlobeNewswire
What is the fair value estimate for Anika Therapeutics Inc. (AKP) stock in 2025CEO Change & Weekly Return Optimization Alerts - Newser
Can Anika Therapeutics Inc. (AKP) stock ride next bull market cycleIPO Watch & Short-Term Swing Trade Alerts - Newser
Dermal Fillers Market Size Report 2032 | AbbVie Inc., Galderma, - openPR.com
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 39%? - Yahoo Finance
Why Anika Therapeutics Inc. (AKP) stock stays on top picksQuarterly Investment Review & Low Drawdown Momentum Ideas - Newser
Is Anika Therapeutics Inc. stock a buy before product launchesJuly 2025 EndofMonth & Verified Technical Signals - Newser
Anika Therapeutics (ANIK) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Anika Therapeutics Inc. stock reacts to global recession fears2025 Earnings Impact & Weekly Market Pulse Updates - Newser
United States Joint Pain Injection Market Surges at 12% CAGR - openPR.com
Understanding the Setup: (ANIK) and Scalable Risk - news.stocktradersdaily.com
Anika Therapeutics Inc.Common Stock (NQ: ANIK - Markets Financial Content
Osteoarthritis Therapeutics Market Key PlayersShare Consolidation Trends & Capital Growth Signals - openPR.com
Anika Therapeutics Reports Mixed Q3 2025 Results - MSN
How Anika Therapeutics Inc. stock responds to policy changes2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Envestnet Asset Management Inc. Boosts Stake in Anika Therapeutics Inc. $ANIK - Defense World
How Anika Therapeutics Inc. (AKP) stock reacts to Fed tighteningMarket Volume Report & Smart Money Movement Alerts - newser.com
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anika Therapeutics Inc Stock (ANIK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):